Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adc Therapeutics Sa (NY: ADCT ) 3.070 +0.250 (+8.87%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Adc Therapeutics Sa < Previous 1 2 3 4 5 6 7 8 Next > Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday December 21, 2022 We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday Via InvestorPlace Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket December 21, 2022 Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed... Via Benzinga ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma December 21, 2022 From ADC Therapeutics SA Via Business Wire Analyst Ratings for ADC Therapeutics November 09, 2022 Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Via Benzinga Analyst Ratings for ADC Therapeutics September 09, 2022 Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Via Benzinga ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer December 19, 2022 From ADC Therapeutics SA Via Business Wire Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal December 04, 2022 Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built... Via Talk Markets Biocytogen Enters into Antibody Agreement with ADC Therapeutics November 28, 2022 From Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022 November 09, 2022 Upgrades Via Benzinga Stocks That Hit 52-Week Lows On Monday November 28, 2022 On Monday, 79 companies reached new 52-week lows. Via Benzinga ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates November 08, 2022 From ADC Therapeutics SA Via Business Wire Expert Ratings for ADC Therapeutics September 09, 2022 ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter: Via Benzinga ADC Therapeutics: Q2 Earnings Insights August 09, 2022 ADC Therapeutics (NYSE:ADCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga ADC Therapeutics to Participate in the Jefferies London Healthcare Conference November 07, 2022 From ADC Therapeutics SA Via Business Wire ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting November 03, 2022 From ADC Therapeutics SA Via Business Wire IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma November 02, 2022 From ADC Therapeutics SA Via Business Wire IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma November 02, 2022 From IGM Biosciences, Inc. Via GlobeNewswire ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer November 01, 2022 From ADC Therapeutics SA Via Business Wire ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022 October 31, 2022 From ADC Therapeutics SA Via Business Wire ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) September 21, 2022 From ADC Therapeutics SA Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 September 21, 2022 Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... Via Benzinga ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma September 16, 2022 From ADC Therapeutics SA Via Business Wire INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm September 14, 2022 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm September 13, 2022 From The Schall Law Firm Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 September 09, 2022 Upgrades Via Benzinga Where ADC Therapeutics Stands With Analysts September 09, 2022 Over the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... Via Benzinga ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference September 06, 2022 From ADC Therapeutics Via Business Wire AMC Entertainment, Pharvaris And Some Other Big Stocks Moving Lower On Monday August 22, 2022 Via Benzinga ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes August 15, 2022 From ADC Therapeutics SA Via Business Wire Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday August 15, 2022 Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.